"There is a median latency of approximately 30 days between exposure to levamisole and development of this clinical syndrome, however there is a wide range between 1 day and time periods exceeding 4 months 1. The severity of the clinical syndrome does not seem to correlate with the exposed dose of levamisole 1."
"In addition to levamisole-induced leukoencephalopathy, levamisole may also be associated with an ANCA vasculitis, which typically presents with cutaneous vasculitis (e.g. purpuric rash), and rarely has other organ (e.g. renal, pulmonary) involvement 6."
"There is a median latency of approximately 30 days between exposure to levamisole and development of this clinical syndrome, however there is a wide range between 1 day and time periods exceeding 4 months 1. The severity of the clinical syndrome does not seem to correlate with the exposed dose of levamisole 1."
"focal neurological deficits (e.g. weakness, ataxia, dysphasia, dysphagia)"
"constitutional symptoms (e.g. fever, headache, myalgias)"
"Generally, patients have multiple, bilateral, asymmetric, and initially patchy and ovoid T2/FLAIR hyperintensities affecting the centrum semiovale, often with a periventricular predominance, and sparing subcortical U-fibres 1-8. In approximately one-half of cases the basal nuclei can be similarly involved, and in approximately one-third of cases the posterior fossa can be similarly involved 1."